At the Axtria Ignite 2025 conference, web editor Nicole Raleigh spoke with Mark Montgomery, VP & international head, ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

There was consternation among the research community yesterday after it emerged that the White House's Office of Management ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

Diagnostics provide the insight, but only a connected pathway turns that insight into real-world impact. That means ensuring ...

The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

This demographic shift is placing immense strain on health and social care systems worldwide, and calls for bold, innovative ...